A decade of profitability provides U.S. expansion foundation

Key points

• Tenth consecutive annual profit declared
• Cash reserves up 12% to $252.055 million
• Dividend of $0.05 per ordinary share declared
• Focus on U.S. expansion strategy

Full summary

Clinuvel Pharmaceuticals Ltd (ASX: CUV) announced its tenth consecutive annual profit for the financial year ended 30 June 2026, with a net profit after tax of $33.917 million, down 6% from the previous year. The company's revenues from ordinary activities declined marginally to $94.024 million, while expenses also decreased to $53.493 million. Cash reserves rose by 12% to $252.055 million, providing financial flexibility for strategic investments and market cycles. The company declared a dividend of $0.05 per ordinary share, marking the ninth consecutive annual dividend. The strong financial performance and cash reserves position the company for expansion in the U.S. market.

Guidance

Net profit after tax $33.917 million, down 6% YOY; Cash reserves $252.055 million, up 12% YOY

Outlook

Clinuvel plans to leverage its strong financial position to pursue expansion in the U.S. market, focusing on strategic investments and market cycles.